A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
NCT00211185
Completed
Study of ONTAK and CHOP (chemotherapy drugs) to find out their ability to make Peripheral T-cell lymphoma disappear (for any period of time) and potentially lengthen life. The study will also compare what kind of side effects these drugs cause and how often they occur. The hypothesis is that patients with newly diagnosed peripheral T-Cell lymphoma, when given ONTAK + CHOP, will tolerate the treatment and will have a 20% improvement in response rate when compared to CHOP alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2020
Locations: Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota
Conditions: Lymphoma, T-Cell, Peripheral
Register for Updates
Stem Cell Transplant for Hemoglobinopathy
NCT00176852
Completed
This study tests the clinical outcomes of one of two preparative regimens (determined by available donor source) in patients with non-malignant hemoglobinopathies. The researchers hypothesize that these regimens will have a positive effect on post transplant engraftment and the incidence of graft-versus-host-disease. Regimen A2 has replaced Regimen A in this study. Two patients were treated on Regimen A but did not have evidence of initial engraftment thus triggering the stopping rule for that... Read More
Gender:
ALL
Ages:
50 years and below
Trial Updated:
02/13/2020
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
Register for Updates
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
NCT00939653
Terminated
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs. Clofarabine will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/07/2020
Locations: Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota
Conditions: Relapsed Acute Myelogenous Leukemia
Register for Updates
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
NCT00354744
Completed
RATIONALE: Drugs used in chemotherapy, such as vincristine, irinotecan, ifosfamide, etoposide, doxorubicin, cyclophosphamide, and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose combination chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase III trial is studying how well giving high-dose co... Read More
Gender:
ALL
Ages:
49 years and below
Trial Updated:
01/15/2020
Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota +2 locations
Conditions: Sarcoma
Register for Updates
Bone Marrow Transplantation in Treating Patients With Leukemia
NCT00006451
Withdrawn
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Randomized phase II/III trial to determine the effectiveness of bone marrow transplantation in treating patients who have leukemia.
Gender:
ALL
Ages:
45 years and below
Trial Updated:
12/31/2019
Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota
Conditions: Graft Versus Host Disease, Leukemia, Lymphoma
Register for Updates
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
NCT02145039
Terminated
This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with advanced and/or high risk diseases.
Gender:
ALL
Ages:
74 years and below
Trial Updated:
12/12/2019
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
Register for Updates
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
NCT00394251
Completed
The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
11/07/2019
Locations: Not set, Minneapolis, Minnesota
Conditions: Breast Cancer
Register for Updates
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00301821
Completed
RATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2019
Locations: Not set, Alexandria, Minnesota +29 locations
Conditions: Lymphoma
Register for Updates
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
NCT01581970
Completed
This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line chemotherapy other than a cetuximab containing regimen will be treated with standard of care weekly cetuximab and twice daily low dose oral cyclophosphamide for 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2019
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Stem Cell Transplantation for Fanconi Anemia
NCT00167206
Terminated
The purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia patients undergoing alternate donor (not a matched sibling) stem cell transplants.
Gender:
ALL
Ages:
Between 1 day and 18 years
Trial Updated:
08/21/2019
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Fanconi Anemia
Register for Updates
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
NCT00066469
Completed
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, prednisone, and methylprednisolone use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining cyclophosphamide and either prednisone or methylprednisolone with rituximab may be effective in treating lymphoproliferative disease following organ... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
07/25/2019
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: Lymphoproliferative Disorder
Register for Updates
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
NCT00004228
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/24/2019
Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota +2 locations
Conditions: Lymphoma
Register for Updates